MaxCyte has signed a strategic platform license with Adicet Bio, granting Adicet non-exclusive research, clinical, and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform. In exchange, MaxCyte will receive platform licensing fees and program-related revenue.
Adicet Bio is developing allogeneic gamma delta T cell therapies for cancer and autoimmune disease treatment. The company’s proprietary process activates and expands specific gamma delta T cell subsets, allowing scalable production of these cell therapies for clinical use. Their approach combines non-viral gene editing with a robust expansion platform to produce cell therapy products designed to address a broad range of cancers and autoimmune disorders.
“We are pleased to support Adicet Bio as they expand their allogeneic gamma delta T cell manufacturing capabilities to include non-viral gene editing delivery,” said Maher Masoud, President and Chief Executive Officer of MaxCyte. “This collaboration underscores the versatility of our platform and its ability to enable the development of next-generation cell therapy candidates with increased efficiency and accessibility.”
According to MaxCyte, the ExPERT™ instrument portfolio delivers high transfection efficiency (the process of introducing nucleic acids into cells), cell viability, and scalability, supporting the development of advanced biological and cellular therapeutics.
Want to keep up on regenerative medicine? Get the weekly newsletter here.
